Log In
Print this Print this

gemcitabine-releasing intravesical system, GemRIS (TAR-200) (formerly TD-210)

  Manage Alerts
Collapse Summary General Information
Company Taris Biomedical LLC
DescriptionDrug-device combination using the Taris system to continuously deliver gemcitabine into the bladder over 7 days
Molecular Target Not applicable
Mechanism of Action 
Therapeutic ModalityMedical Devices: Drug/device combination
Latest Stage of DevelopmentPhase I
Standard IndicationBladder cancer
Indication DetailsTreat muscle invasive bladder cancer; Treat non-muscle invasive bladder cancer (NMIBC)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today